Multi-year collaboration will enable development of complex, cutting-edge cell therapies and armoring technologies for solid tumor targets
- Collaboration propels momentum of expansion of cGMP facilities at Roswell Park
- CAR T-cell therapies harness power of immune system to fight cancer
- Roswell Park anticipated to serve as site for Phase I, II clinical trials
BUFFALO, N.Y. and SOMERVILLE, Mass. – Roswell Park Comprehensive Cancer Center and Generate:Biomedicines announce a strategic collaboration to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors. In ovarian cancer alone, an estimated 314,000 women worldwide are diagnosed and over 200,000 women die each year.
Under the collaboration agreement, Roswell Park and Generate:Biomedicines will contribute toward creating optimized cell therapies, where a patient’s T cells are engineered to recognize and kill tumors. In recent years, CAR T-cells have seen remarkable successes for the treatment of liquid tumors, such as leukemia and lymphoma, including FDA approvals; however, successful treatment of solid tumors remains a major challenge for the field.
The collaboration combines the programmability and scalability of The Generate Platform and Roswell Park’s expertise in cell therapy design, clinical development, and manufacturing to bring best-in-class cell therapies to patients. The collaboration continues the significant momentum associated with the recently announced expansion, supported in part by New York State funds, that will make Roswell Park’s Current Good Manufacturing Practice (cGMP) facilities the largest academic cell therapy center in the United States.
“This is a powerful combination that brings together Roswell Park’s world-leading expertise in cell therapy manufacturing and our technology and computational power,” says Generate:Biomedicines’ Executive Vice President, Research & Development, Alex Snyder, MD. “Dr. Brentjens – whose lab played a foundational role in development of the currently approved therapies – together with Dr. Davila and their team are among the world’s leading experts in cell therapy. Together we will deliver novel CAR T-cell therapeutics rapidly to change outcomes for patients with advanced solid tumors.”
“This collaboration with Generate:Biomedicines will allow us to harness the power of generative AI to rapidly advance our research to make groundbreaking cancer therapies for patients who are in need of new treatment options,” says Renier Brentjens, MD, PhD, Deputy Director and The Katherine Anne Gioia Endowed Chair in Cancer Medicine at Roswell Park.
“Getting these complex new therapies to patients can often be a lengthy and complicated process requiring versatile solutions. By tapping into The Generate Platform, we see a great opportunity to efficiently and effectively advance innovative oncology treatments from idea to clinic,” adds Marco Davila, MD, PhD, Senior Vice President and Associate Director for Translational Research at Roswell Park.
Under the agreement terms, Roswell Park and Generate:Biomedicines will share research and development expenses as well as profits generated through commercialization of products that emerge from the collaboration. It is anticipated that Roswell Park will serve as a site and recommend lead investigators for Phase I and II clinical trials.
About Roswell Park Comprehensive Cancer Center:
From the world’s first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide. Driven to eliminate cancer’s grip on humanity, the Roswell Park team of 4,000 makes compassionate, patient-centered cancer care and services accessible across New York State and beyond. Founded in 1898, Roswell Park was among the first three cancer centers nationwide to become a National Cancer Institute-designated comprehensive cancer center and is the only one to hold this designation in Upstate New York. To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit www.roswellpark.org, call 1-800-ROSWELL (1-800-767-9355) or email ASKRoswell@RoswellPark.org.
Generate:Biomedicines is the first drug generation company, pioneering a machine learning-powered generative biology platform with the ability to create new drugs on demand across a wide range of biologic modalities. The Generate Platform – which is a continuous loop to generate, build, measure, and learn – can drastically increase the speed at which targets and therapeutics are identified and validated. This will improve the specificity of target engagement by generated proteins and reduce the time and cost of identifying and developing clinical candidates. Generate:Biomedicines was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020. Learn more about Generate:Biomedicines by visiting https://generatebiomedicines.com/ or following the company on Twitter and LinkedIn.
Rebecca Vogt, Media Relations Specialist